Workshop Co-organized by
IABS and Japan Science and Technology Agency

Organizing Committee

Takao Hayakawa 1)
Kinki Univ., Japan
Takashi Aoi
Kobe Univ., Japan
Akifumi Matsuyama
FBRI, Japan
John Petricciani
IABS President, USA
Yoji Sato
National Institute of Health Sciences, Japan
Yuzo Toda
FIRM Chairperson, Japan
Masayuki Yamato
Tokyo Women’s Medical Univ., Japan


Program Committee

Takao Hayakawa 1)
Kinki Univ., Japan
Takashi Aoi
Kobe Univ., Japan
Mira Choi
MFDS, Korea
Hyung Min Chung
Konkuk Univ., Korea
Joyce Frey-Vasconcells
Frey-Vasconcells Consulting, USA
Karin Hoogendoorn
Janssen Biologics, Netherland
Surapol Issaragrilsil
Mahidol Univ., Thailand
Akifumi Matsuyama
FBRI, Japan
John Petricciani
IABS President, USA
Matthias Renner
PEI, Germany
Anthony Ridgway
Health Canada, Canada
Yoji Sato
National Institute of Health Sciences, Japan
Glenn Smith
TGA, Australia
Glyn Stacey
UKSCB/NIBSC, UK
Yuzo Toda
FIRM Chairperson, Japan
Jean-Hugues Trouvin
Univ. Paris Descartes, France
Masayuki Yamato
Tokyo Women’s Medical Univ., Japan

1) Chair of Cell & Gene Therapy Committee, IABS

Meeting management:

IABS
Geneva, Switzerland




Objectives of the Workshop

This meeting will bring together an outstanding and diverse group of speakers, from regulatory agencies, industry, academia, all of whom are at the forefront of the cell therapy field. The meeting intends to increase awareness of the diverse views of our global partners, as well as to promote international dialogue and exchange of information and points of view in this evolving field. The starting point will be to share a common recognition of the essential scientific elements for early product development, evaluation and control of cell therapy products. Then we will move on to identify very critical points/issues to be solved, improved, and/or developed in terms of technical as well as scientific regulation in order to facilitate the availability of products in a rational and timely manner, which will be valuable globally to public health.